Scarica l'app Stockscreener
3.91
0.51%
-0.02
Dopo l'orario di chiusura:
3.92
0.010
+0.26%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IOVA Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.93
Aprire:
$3.97
Volume 24 ore:
23.65M
Relative Volume:
1.66
Capitalizzazione di mercato:
$1.75B
Reddito:
$285.55M
Utile/perdita netta:
$-353.86M
Rapporto P/E:
-4.1154
EPS:
-0.9501
Flusso di cassa netto:
$-305.02M
1 W Prestazione:
-1.26%
1M Prestazione:
+15.34%
6M Prestazione:
+58.94%
1 anno Prestazione:
+91.67%
Intervallo 1D:
$3.85
$4.05
Intervallo di 1 settimana:
$3.80
$4.23
Portata 52W:
$1.66
$5.63
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Nome
Iovance Biotherapeutics Inc
Settore
Industria
Telefono
(650) 260-7120
Indirizzo
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
3.91 | 1.75B | 285.55M | -353.86M | -305.02M | -0.9501 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-25 | Aggiornamento | Citizens | Mkt Perform → Mkt Outperform |
| 2025-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-16 | Downgrade | UBS | Buy → Neutral |
| 2025-05-12 | Downgrade | Truist | Buy → Hold |
| 2025-05-09 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-07-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-09-18 | Reiterato | Barclays | Overweight |
| 2023-05-30 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
| 2023-01-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-31 | Iniziato | Guggenheim | Neutral |
| 2022-08-18 | Ripresa | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-12-07 | Ripresa | Cowen | Outperform |
| 2021-06-10 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Downgrade | Stifel | Buy → Hold |
| 2021-05-03 | Iniziato | Truist | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2021-03-08 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Iniziato | Mizuho | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-02-26 | Reiterato | Oppenheimer | Outperform |
| 2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-10-01 | Iniziato | Stifel | Buy |
| 2019-04-29 | Iniziato | Piper Jaffray | Overweight |
| 2019-02-28 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-07 | Iniziato | Robert W. Baird | Outperform |
| 2018-12-31 | Ripresa | B. Riley FBR | Buy |
| 2018-07-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-04-10 | Aggiornamento | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Reiterato | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-01 | Reiterato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie
Iovance Biotherapeutics grants stock options to 27 new employees under Nasdaq rules. - Pluang
Iovance Biotherapeutics Grants Inducement Stock Options to 27 New Employees - Quiver Quantitative
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Iovance Biotherapeutics Inc Files For Mixed Shelf - TradingView
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
Iovance Biotherapeutics Inc: Sale Agreement P - Moomoo
Director Michael Weiser granted 90,316 deferred RSUs at IOVANCE (NASDAQ: IOVA) - Stock Titan
180,632 deferred stock units granted to Iovance (IOVA) director Dukes - Stock Titan
IOVANCE BIOTHERAPEUTICS (IOVA) director receives 90,316 deferred stock units - Stock Titan
Iovance Biotherapeutics (IOVA) grants 90,316 deferred stock units to director - Stock Titan
IOVANCE (IOVA) awards 15,000 restricted stock units to Chief Regulatory Officer Raj K. Puri - Stock Titan
Iovance Biotherapeutics (NASDAQ: IOVA) files $89.65M at-the-market common stock sale - Stock Titan
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
Iovance Biotherapeutics Inc (IOVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Iovance Biotherapeutics Inc (IOVA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Iovance Biotherapeutics Inc (IOVA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Why Is IOVA Stock Falling Today? - Stocktwits
Iovance Biotherapeutics Inc (IOVA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Iovance Biotherapeutics Inc (IOVA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Iovance Biotherapeutics Inc (IOVA) Institutional Confidence - TradingKey
Iovance Biotherapeutics Inc (IOVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Iovance Biotherapeutics: Commercial, Clinical, And Regulatory Tailwinds (NASDAQ:IOVA) - Seeking Alpha
H.C. Wainwright Remains a Buy on Iovance Biotherapeutics (IOVA) - Yahoo Finance
IOVA Stock Price, Quote & Chart - ChartMill
5 Best Penny Stocks That Could Skyrocket in 2026 - Insider Monkey
What Iovance Biotherapeutics (IOVA)'s Australia Amtagvi Nod and New TIL Trial Mean for Shareholders - Sahm
Amtagvi Approval Boosted Iovance Biotherapeutics, Inc. (IOVA), But Can the Rally Last? - Yahoo Finance
IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Chart - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
Iovance Biotherapeutics (IOVA) reports Q1 loss, lags revenue estimates - MSN
Iovance Biotherapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Iovance Shareholders Approve Expanded Capital Flexibility and Governance - TipRanks
Iovance (NASDAQ: IOVA) gains Australian Amtagvi approval as shareholders back larger share pool - Stock Titan
Iovance Biotherapeutics (IOVA) Advances Next-Generation TIL Pipeline With FDA Clearance for IOV-5001 - Insider Monkey
IOVA: All proposals passed; strong growth, robust pipeline, and focus on revenue and margin improvement - TradingView
Iovance Biotherapeutics: Progress With Caveats (NASDAQ:IOVA) - Seeking Alpha
Iovance rises as Australia approves melanoma therapy Amtagvi - MSN
IOVANCE (NASDAQ: IOVA) interim CEO reports RSU vesting and tax-share withholding - Stock Titan
IOVANCE (IOVA) Chief Medical Officer logs RSU vesting, tax-withheld shares in Form 4 - Stock Titan
Iovance (NASDAQ: IOVA) CRO reports RSU vesting and tax share withholding - Stock Titan
IOVANCE (NASDAQ: IOVA) COO RSUs vest; 3,976 shares withheld for tax - Stock Titan
IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits
Iovance’s Amtagvi® (lifileucel) receives approval for treatment of Advanced Melanoma in Australia - BioSpectrum Asia
Iovance Biotherapeutics, Inc. (IOVA) a Top Penny Stock to Buy on Amtagvi Strong Adoption - Yahoo Finance
Iovance Biotherapeutics (IOVA) Sees Revenue Surge 45% on Amtagvi Growth Despite Analyst Price Target AdjustmentEarnings Call Highlights - newsline.com
A Look At Iovance Biotherapeutics (IOVA) Valuation After Australian Conditional Approval For Amtagvi - Yahoo Finance
Iovance Biotherapeutics (IOVA) Slides 3.4% as Biotech Sector Faces Renewed PressureSmart Money Flow Stocks - newsline.com
Iovance Biotherapeutics (IOVA) Up 11% Since Q1 2026, Does it Have Further Upside Potential? - Insider Monkey
Is Iovance Biotherapeutics, Inc. (IOVA) One of the Most Shorted Small-Cap Stocks to Buy Now? - Insider Monkey
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
Why Did IOVA Stock Gain Pre-Market Today? - Stocktwits
Iovance Biotherapeutics Inc Azioni (IOVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):